COVID-19-Associated Paediatric Inflammatory Multisystem Syndrome (PIMS-TS) in Intensive Care: A Retrospective Cohort Trial (PIMS-TS INT)
Tereza Musilová,
Jakub Jonáš,
Tomáš Gombala,
Jan David,
Filip Fencl,
Eva Klabusayová,
Jozef Klučka,
Milan Kratochvíl,
Pavla Havránková,
Adéla Vrtková,
Kateřina Slabá,
Jana Tučková,
Lukáš Homola,
Petr Štourač,
Tomáš Vymazal
Affiliations
Tereza Musilová
Department of Paediatric Anaesthesiology and Intensive Care Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
Jakub Jonáš
Department of Anaesthesiology, Resuscitation and Intensive Care Medicine, 2nd Medical Faculty, Charles University and University Hospital Motol, 150 06 Prague, Czech Republic
Tomáš Gombala
Department of Pediatrics, Klinik Donaustadt, Langobardenstraße 122, 1020 Vienna, Austria
Jan David
Department of Pediatrics, 2nd Medical Faculty, Charles University and University Hospital Motol, 150 06 Prague, Czech Republic
Filip Fencl
Department of Pediatrics, 2nd Medical Faculty, Charles University and University Hospital Motol, 150 06 Prague, Czech Republic
Eva Klabusayová
Department of Paediatric Anaesthesiology and Intensive Care Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
Jozef Klučka
Department of Paediatric Anaesthesiology and Intensive Care Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
Milan Kratochvíl
Department of Paediatric Anaesthesiology and Intensive Care Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
Pavla Havránková
Department of Paediatric Anaesthesiology and Intensive Care Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
Adéla Vrtková
Department of Applied Mathematics, Faculty of Electrical Engineering and Computer Science, VSB Technical University of Ostrava (Czech Republic), 708 00 Ostrava, Czech Republic
Kateřina Slabá
Department of Paediatrics, University Hospital Brno and Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
Jana Tučková
Department of Paediatrics, University Hospital Brno and Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
Lukáš Homola
Department of Pediatric Infectious Diseases, University Hospital Brno, Kamenice 5, 625 00 Brno, Czech Republic
Petr Štourač
Department of Paediatric Anaesthesiology and Intensive Care Medicine, University Hospital Brno and Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
Tomáš Vymazal
Department of Anaesthesiology, Resuscitation and Intensive Care Medicine, 2nd Medical Faculty, Charles University and University Hospital Motol, 150 06 Prague, Czech Republic
Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS) is a new disease in children and adolescents that occurs after often asymptomatic or mild COVID-19. It can be manifested by different clinical symptomatology and varying severity of disease based on multisystemic inflammation. The aim of this retrospective cohort trial was to describe the initial clinical presentation, diagnostics, therapy and clinical outcome of paediatric patients with a diagnosis of PIMS-TS admitted to one of the 3 PICUs. All paediatric patients who were admitted to the hospital with a diagnosis of paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) during the study period were enrolled in the study. A total of 180 patients were analysed. The most common symptoms upon admission were fever (81.6%, n = 147), rash (70.6%, n = 127), conjunctivitis (68.9%, n = 124) and abdominal pain (51.1%, n = 92). Acute respiratory failure occurred in 21.1% of patients (n = 38). Vasopressor support was used in 20.6% (n = 37) of cases. Overall, 96.7% of patients (n = 174) initially tested positive for SARS-CoV-2 IgG antibodies. Almost all patients received antibiotics during in-hospital stays. No patient died during the hospital stay or after 28 days of follow-up. Initial clinical presentation and organ system involvement of PIMS-TS including laboratory manifestations and treatment were identified in this trial. Early identification of PIMS-TS manifestation is essential for early treatment and proper management of patients.